Alumis Inc. Financial Update: Q3 Highlights
Alumis Inc. (NASDAQ: ALMS), a clinical-stage biopharmaceutical firm specializing in innovative therapies for immune-mediated diseases, has revealed its financial results for the third quarter of 2025. The company is making notable strides in developing targeted treatments, showcasing its commitment to improving patient health outcomes.
According to Martin Babler, the President and CEO of Alumis, this phase marks a significant moment for the company. The upcoming topline data from the Phase 3 ONWARD study of envudeucitinib (envu) in moderate-to-severe plaque psoriasis is expected to be shared early in the first quarter of 2026, with additional data from the Phase 2b LUMUS trial in systemic lupus erythematosus anticipated later in the third quarter of the same year.
Babler elaborated on the potential of these data readouts, which could validate the unique properties of envu and create broader opportunities in the treatment of immune-mediated diseases, thus making a substantial impact on both the company and the patients it serves.
Significant Developments in the Pipeline
Alumis is proud to present its strong pipeline, which includes late-stage clinical programs and promising preclinical candidates that underscore the efficiency of its precision immunology R&D approach. The ongoing development of two next-generation oral TYK2 inhibitors enhances its capacity to address various immune-mediated conditions.
Envudeucitinib (Envu)
One key highlight is envudeucitinib, a selective oral TYK2 inhibitor aimed at treating various immune-mediated diseases, including psoriasis and lupus. Recent publications in the Journal of the American Academy of Dermatology detail the results from the Phase 2 STRIDE clinical trial. The findings indicate impressive response rates and a favorable safety profile, underlining envu’s potential as a viable treatment for moderate-to-severe plaque psoriasis.
A-005: A Novel Approach in Neuroinflammation
A-005, another promising candidate from Alumis, is recognized as a fully CNS-penetrant oral TYK2 inhibitor, aimed at addressing neuroinflammatory and neurodegenerative diseases. A recent presentation at the ECTRIMS Conference discussed its favorable pharmacokinetic profile and significant TYK2 inhibition, building anticipation for a Phase 2 clinical trial in multiple sclerosis.
Lonigutamab's Progress and Expected Outcomes
Another noteworthy program is Lonigutamab, a next-generation subcutaneous therapy targeting IGF-1R, developed for thyroid eye disease. Recent results from a Phase 1/2 proof-of-concept study presented at the ASOPRS annual meeting highlighted its safety, efficacy, and quality of life improvements for patients.
Upcoming Milestones to Watch
Looking ahead, Alumis has set out several anticipated milestones within the remainder of 2025 and into 2026:
- The ONWARD1 and ONWARD2 topline data for moderate-to-severe plaque psoriasis are slated for release early next year.
- In the third quarter of 2026, data from the LUMUS study in lupus should be available.
- Alumis plans to establish a once-daily formulation for envu by the end of 2025.
- A-005's Phase 2 trial in multiple sclerosis is expected to begin in the first half of 2026.
- Continuous evaluation of the Lonigutamab program is underway, alongside clinical data for an internally developed program anticipated later in 2026.
Financial Overview of Q3 2025
As of September 30, 2025, Alumis reported cash and marketable securities amounting to $377.7 million. The revenues for the quarter included $2.1 million from collaborations, stemming from a partnership with Kaken Pharmaceutical Co., Ltd.
Research and development expenses totaled $97.8 million, reflecting a rise primarily due to increased contract research and clinical trial costs associated with envu and other projects.
General and administrative expenses reached $19.5 million, driven by severance costs and staffing needs related to the recent merger with ACELYRIN.
In the third quarter, Net loss stood at $110.8 million, compared to a loss of $93.1 million during the same period the previous year. Notably, the company recognized $6.3 million in total expenses linked to the merger for the quarter, a figure that included stock-based compensation costs.
Looking Forward: Financial Guidance
Alumis remains optimistic about its financial future, with projections indicating that existing cash reserves will support the advancement of its research pipeline and operational costs through 2027. This outlook includes the funding necessary for upcoming clinical data readouts and further operational expenditures.
Conclusion
Alumis Inc. is taking confident steps toward achieving significant milestones in the biopharmaceutical landscape. With a robust pipeline that shows great promise, Alumis strives to innovate and transform the treatments available for patients with immune-mediated diseases. The company is committed to continuous improvement and is dedicated to enhancing patient outcomes through groundbreaking therapies.
Frequently Asked Questions
What is the focus of Alumis Inc.?
Alumis Inc. specializes in developing next-generation targeted therapies for patients suffering from immune-mediated diseases.
What is envudeucitinib?
Envudeucitinib is a highly selective oral TYK2 inhibitor in development for treating moderate-to-severe plaque psoriasis and systemic lupus erythematosus.
What milestone is Alumis expecting in 2026?
Alumis is anticipating topline data from the LUMUS clinical trial in systemic lupus erythematosus in the third quarter of 2026.
How is Alumis’s financial health as of 2025?
As of September 30, 2025, Alumis reported cash, cash equivalents, and marketable securities of $377.7 million.
What are the significant expenses reported in Q3 2025?
Research and development expenses for Q3 2025 were $97.8 million, mostly due to increased trial and contract research costs.
